Ligandal
Main focus: Novel delivery technologies
Company stage: Pre-clinical
Diseases: Undisclosed
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: San Francisco, CA, US
Website: https://www.ligandal.com/
Ligandal is a US-based, privately held biotech company focused on improving delivery systems for gene therapies. Ligandal creates bioinspired nanomaterials that more effectively deliver CRISPR reagents into the nucleus of T cells, which is the company's main target cell. The nanomaterials are developed from ligand-binding motifs derived from natural proteins interacting with the protein of interest.